ClinicalTrials.gg
CompletedNCT05890976OASIS 3Updated Jan 22, 2026

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

A Phase 3 interventional study of Semaglutide and Semaglutide Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
39th of 143
200 · median 100
Started
2023
with 14 others
Phase 3
42 of 143
10 open now
Registered
65th of 143
by date
Lead sponsor
41 of 143
Novo Nordisk A/S

Among the 143 studies testing semaglutide in Obesity, this one is the 39th largest by enrollment, is one of 15 that started in 2023, is one of 42 in phase 3, and was the 65th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks.

In addition to taking the medicine, participants will have talks with study staff about:

  • Healthy food choices
  • How to be more physically active
  • What participants can do to lose weight This study will last for about 1 year.
03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 200 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female, age greater than or equal to 18 years at the time of signing informed consent.
  • (BMI) of

    1. greater than or equal to 28.0 kilogram per meter square (kg/m\^2) or
    2. greater than or equal to 24.0 kg/m\^2 with greater than or equal to 1 weight-related comorbidity (treated or untreated). Weight-related comorbidities should be hypertension, T2D, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

For participants with T2D at screening the following inclusion criteria apply in addition to criteria 1- 4:

  • Diagnosed with T2D greater than or equal to 180 days prior to screening.
  • Treated with either diet and exercise alone or stable treatment (same drug(s) or active ingredient, dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic drugs (OAD)s alone or in any combination (metformin, α-glucosidase (AGI), sulphonylureas (SU), glinides, SGLT2i (sodium-glucose co-transporter 2 inhibitor) or glitazone).
  • 7.0 - 10.0 percent (53 - 86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening.

Exclusion criteria

Exclusion Criteria:

Participants without T2D at screening:

  • greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
  • Treatment with glucose-lowering agent(s) within 90 days prior to screening.

Participants with T2D at screening:

  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Renal impairment measured as estimated (eGFR) value of lesser than 30 milli litre per min/1.73 square metre (mL/min/1.73 m\^2) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease Improving Global Outcomes (KDIGO) 2012 classification by the central laboratory at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Semaglutide 50 mg

    Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 44 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), 25 mg (weeks 13 to 16) and 50 mg (weeks 17 to 44).

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide Placebo

    Participants will receive placebo tablets matched to semaglutide orally once daily for 44 weeks.

    Drug: Semaglutide Placebo

Interventions

  • Participants will receive semaglutide tablets orally once daily for 44 weeks.

  • DrugSemaglutide Placebo

    Participants will receive placebo matched to semaglutide.

07

What researchers measure

Primary outcomes

  1. Relative Change in Body Weight

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  2. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 5 Percent

    Measured as count of participants

    Time frame: At end of treatment (week 44)

Secondary outcomes

  1. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 10 Percent

    Measured as count of participants

    Time frame: At end of treatment (week 44)

  2. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 15 Percent

    Measured as count of participants

    Time frame: At end of treatment (week 44)

  3. Number of Participants Who Achieve (Yes/No): Body Weight Reduction Greater Than or Equal to 20 Percent

    Measured as count of participants

    Time frame: At end of treatment (week 44)

  4. Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite- CT) - Physical Function Domain

    IWQOL-Lite-CT is a 20-item obesity-specific PRO measure used to assess the impact of body weight changes on patient's physical and psychosocial functioning in three composite scores (Physical Function, Physical and Psychosocial) and a Total score.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  5. Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite- CT) - Total score

    IWQOL-Lite-CT is a 20-item obesity-specific PRO measure used to assess the impact of body weight changes on patient's physical and psychosocial functioning in three composite scores (Physical Function, Physical and Psychosocial) and a Total score.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  6. Change in Impact of Weight on Daily Activities Quesionnaire (IWDAQ) - Total Score

    IWDAQ is a 18-item obesity-specific PRO measure developed to evaluate daily activity limitations associated with excess weight. It uses an adaptive questionnaire design where the participant chooses the three IWDAQ activities they would most like to improve with weight loss and rate the degree of limitations in each of the three activities at baseline. The same three activities are assessed for degree of limitations at follow-up to allow for tracking of activities relevant to each individual.

    Time frame: From randomisation (week 0) to end-of-treatment (week 44)

  7. Change in Body Mass Index (BMI)

    Measured in kilogram per square meter (kg/m\^2)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  8. Change in Waist Circumference

    Measured in centimeter (cm)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  9. Change in Systolic Blood Pressure

    Measured in millimeter of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  10. Change in Diastolic Blood Pressure

    Measured in mmHg

    Time frame: From randomisation (week 0) to end of treatment (week 44)

  11. Change in Glycated Haemoglobin (HbA1c)

    Measured in percentage point (%-point)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  12. Change in Fasting Plasma Glucose

    Measured as milligrams per decilitre (mg/dL)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  13. Change in Fasting Serum Insulin

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  14. Change in Total Cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  15. Change in High-density Lipoprotein (HDL) Cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  16. Change in Low-density Lipoproteins (LDL) Cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  17. Change in Very Low-density Lipoproteins (VLDL) Cholesterol

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  18. Change in Triglycerides

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  19. Change in Free Fatty Acids

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  20. Change in High Sensitivity C-reactive Protein (hsCRP)

    Measured as ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 44)

  21. Change in waist-height ratio (WtHR)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  22. Number of Treatment Emergent Adverse Events(TEAE's)

    Measured as count of events

    Time frame: From baseline (week 0) to end of treatment (week 44)

  23. Number of Treatment Emergent Serious Adverse Events(TESAE's)

    Measured as count of events

    Time frame: From baseline (week 0) to end of study (week 51)

  24. AUC 0-24h,sema,50mg,ss: Area Under The Semaglutide-Time Curve (0-24h) During a Dosing Interval at Steady State

    Measured as hours\*nanomoles per litre (h\*nmol/L)

    Time frame: Week 20

  25. Cmax,sema,50mg,ss: Maximum Concentration at Steady State of Semaglutide 50 mg

    Measured as nanomoles per litre (nmol/L)

    Time frame: Week 20

08

Study locations

16 sites
  • Peking University People's Hospital-Endocrinology
    Beijing, Beijing Municipality 100044, China
  • Beijing Friendship Hospital, Capital Medical University-Endocrinology
    Beijing, Beijing Municipality 100050, China
  • Chongqing University Three Gorges Hospital
    Chongqing, Chongqing Municipality 404000, China
  • Huizhou Central People's Hospital-Endocrinology
    Huizhou, Guangdong 516001, China
  • Huaihe Hospital of Henan University-Endocrinology
    Kaifeng, Henan 475000, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 450062, China
  • Taihe Hospital-Endocrinology
    Shiyan, Hubei 442008, China
  • The First People's Hospital of Changde City-Endocrinology
    Changde, Hunan 415003, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213003, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • Jinan Central Hospital
    Ji'nan, Shandong 250013, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Huashan Hospital Fudan University-Endocrinology
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Pudong New Area People's Hospital-Endocrinology
    Shanghai, Shanghai Municipality 201200, China
  • General Hospital of Tianjin Medical University-Endocrinology
    Tianjin, Tianjin Municipality 300052, China
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jan 2025, 19 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 6, 2023
StartActual
May 30, 2023
Primary completionActual
Jan 16, 2025
CompletionActual
Jan 16, 2025
Results delay requested
Jan 15, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05890976
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
May 30, 2023
Primary completion
Jan 16, 2025
Completion
Jan 16, 2025
Last update
Jan 22, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion